• 1
    Wingo PA, Ries LA, Parker SL, Heath CWJr. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 1998; 7: 27182.
  • 2
    Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002; 62: 214150.
  • 3
    Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002; 37: 1539.
  • 4
    Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P. Human estrogen receptor cDNA: sequence,expression and homology to v-erbA. Nature 1986; 320: 1349.
  • 5
    Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986; 231: 11504.
  • 6
    Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 8359.
  • 7
    Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995; 83: 8517.
  • 8
    Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 45186.
  • 9
    Russo J, Hu YF, Yang X, Russo IH. Developmental,cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr 2000; 27: 1737.
  • 10
    Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 2001; 98: 197202.
  • 11
    Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, Rochefort H, Maudelonde T. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58: 536773.
  • 12
    Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 1999; 96: 57227.
  • 13
    Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 1999; 155: 6417.
  • 14
    Cheng YW, Chen CY, Lin P, Huang KH, Lin TS, Wu MH, Lee H. DNA adduct level in lung tissue may act as a risk biomarker of lung cancer. Eur J Cancer 2000 Jul; 36: 13818.
  • 15
    Cheng YW, Hsieh LL, Lin PP, Chen CP, Chen CY, Lin TS, Su JM, Lee H. Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ Mol Mutagen 2001; 37: 30410.
  • 16
    Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 1998; 3: 8594.
  • 17
    McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978; 5: 42833.
  • 18
    Davidson NE. Combined endocrine therapy for breast cancer—new life for an old idea? J Natl Cancer Inst 2000; 92: 85960.
  • 19
    Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994; 54: 25525.
  • 20
    Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996; 2: 80510.
  • 21
    Issa JP, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 1996; 56: 36558.
  • 22
    Belinsky SA, Snow SS, Nikula KJ, Finch GL, Tellez CS, Palmisano WA. Aberrant CpG island methylation of the p16 (INK4a) and estrogen receptor genes in rat lung tumors induced by particulate carcinogens. Carcinogenesis 2002; 23: 3359.
  • 23
    Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 98216.
  • 24
    Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 1998; 58: 25159.
  • 25
    Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 171749.
  • 26
    Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000; 60: 43468.
  • 27
    Li Q, Kopecky KJ, Mohan A, Willman CL, Appelbaum FR, Weick JK, Issa JP. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 1999; 5: 107784.
  • 28
    Hori M, Iwasaki M, Shimazaki J, Inagawa S, Itabashi M. Assessment of hypermethylated DNA in two promoter regions of the estrogen receptor alpha gene in human endometrial diseases. Gynecol Oncol 2000; 76: 8996.
  • 29
    Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res 2000; 60: 7026.
  • 30
    Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 2002; 94: 75561.
  • 31
    Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T. Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. Jpn J Cancer Res 2002; 93: 110713.
  • 32
    Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han J, Park J. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 2003; 63: 37436.
  • 33
    Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002; 188: 12540.
  • 34
    Sakai N, Maruyama T, Sakurai R, Masuda H, Yamamoto Y, Shimizu A, Kishi I, Asada H, Yamagoe S, Yoshimura Y. Involvement of histone acetylation in ovarian steroid-induced decidualization of human endometrial stromal cells. J Biol Chem 2003; 278: 1667582.
  • 35
    Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S, Dahiya R. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 2002; 94: 3849.
  • 36
    Levenson AS, Jordan VC. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 1994; 51: 22939.
  • 37
    Warner M, Saji S, Gustafsson JA. The normal and malignant mammary gland: a fresh look with ER beta onboard. J Mammary Gland Biol Neoplasia 2000; 5: 28994.
  • 38
    Liu G, Schwartz JA, Brooks SC. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res 2000; 60: 18104.
  • 39
    Geisler JP, Wiemann MC, Miller GA, Zhou Z, Geisler HE. Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary. J Surg Oncol 1995; 59: 457.
  • 40
    Martin JD, Hahnel R, McCartney AJ, Woodings TL. The effect of estrogen receptor status on survival in patients with endometrial cancer. Am J Obstet Gynecol 1983; 147: 3224.
  • 41
    Clark GM, McGuire WL. Prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1983; 3( Suppl): S6972.
  • 42
    Yang CH, Cheng AL, Yeh KH, Yu CJ, Lin JF, Yang PC. High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced,inoperable nonsmall cell lung carcinoma. Cancer 1999; 86: 41520.
  • 43
    Chen YM, Perng RP, Yang KY, Lin WC, Wu HW, Liu JM, Tsai CM. Whang-Peng J. A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer. Am J Clin Oncol 2000; 23: 137.